Approved Risk Evaluation and Mitigation Strategies (REMS)

Approved Risk Evaluation and Mitigation Strategies (REMS)

Xeljanz (tofacitinib) 

NDA #203214

View the Xeljanz Prescribing Information and Medication Guide at DailyMed 
View Xeljanz's Regulatory Information at Drugs@FDA

What do participants need to do?

Healthcare providers should read the relevant Medication Guide or communication materials provided by the application holder to learn about the risk.

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers: